Announcements

01.10.2018

Valsartan: Extended investigations – products on Swiss market tested to date give no cause for concern

Like the previously analysed products with valsartan, products with losartan, olmesartan and candesartan that have been investigated do not contain elevated NDMA levels.

30.09.2018

Revision of the Therapeutic Products Act (TPA): Publication of the specification documents and forms for authorisation applications

Owing to the revision of the TPA and the corresponding implementing ordinances (Therapeutic Products Ordinance Package IV), Swissmedic has adapted the specification documents and forms for authorisation applications.

21.09.2018

Therapeutic Products Ordinance Package IV: Publication of the ordinances

The Federal Council has approved Therapeutic Products Ordinance Package IV. Swissmedic and the FOPH publish the revised documents.

21.09.2018

Implementing regulations in the therapeutic products area: Start of consultation procedure for Federal Council and Agency Council Ordinances

The consultation procedure for the Therapeutic Products Ordinance Package IV will last from 21 June May to 20 October 2017.

18.09.2018

Publikumswerbung für zugelassene Komplementärarzneimittel ohne Indikation

Regulierende Massnahmen von Swissmedic

14.09.2018

Swissmedic agrees closer collaboration in therapeutic products field with Dutch partner authority

Swissmedic intends to intensify collaboration with its partner authority in the Netherlands.

24.08.2018

Medicinal products containing valsartan: First analytical results

Preparations with valsartan that are currently available on the market satisfy the requirements

17.08.2018

Investigation of Valsartan medicinal products for evidence of active substance contamination – an update

Additional recall of batches in Europe – no products in Switzerland affected to date

01.10.2018

Valsartan: Extended investigations – products on Swiss market tested to date give no cause for concern

Like the previously analysed products with valsartan, products with losartan, olmesartan and candesartan that have been investigated do not contain elevated NDMA levels.

30.09.2018

Revision of the Therapeutic Products Act (TPA): Publication of the specification documents and forms for authorisation applications

Owing to the revision of the TPA and the corresponding implementing ordinances (Therapeutic Products Ordinance Package IV), Swissmedic has adapted the specification documents and forms for authorisation applications.

21.09.2018

Therapeutic Products Ordinance Package IV: Publication of the ordinances

The Federal Council has approved Therapeutic Products Ordinance Package IV. Swissmedic and the FOPH publish the revised documents.

21.09.2018

Implementing regulations in the therapeutic products area: Start of consultation procedure for Federal Council and Agency Council Ordinances

The consultation procedure for the Therapeutic Products Ordinance Package IV will last from 21 June May to 20 October 2017.

18.09.2018

Publikumswerbung für zugelassene Komplementärarzneimittel ohne Indikation

Regulierende Massnahmen von Swissmedic

14.09.2018

Swissmedic agrees closer collaboration in therapeutic products field with Dutch partner authority

Swissmedic intends to intensify collaboration with its partner authority in the Netherlands.

24.08.2018

Medicinal products containing valsartan: First analytical results

Preparations with valsartan that are currently available on the market satisfy the requirements

17.08.2018

Investigation of Valsartan medicinal products for evidence of active substance contamination – an update

Additional recall of batches in Europe – no products in Switzerland affected to date

Last modification 16.11.2017

Top of page